ALNY monthly performance report
Explore ALNY's monthly returns, drawdown, and seasonality trends — updated every month.
ALNY monthly report
—
Key takeaways
- Alnylam Pharmaceuticals (ALNY) closed September 2026 at $239.56, down 0.47% for the month and −47.02% over the trailing 12 months.
- Year-to-date, ALNY is −39.76%, underperforming the S&P 500 which has returned +11.70% YTD.
- The stock is trading −24.33% versus its 200-day moving average ($316.57), a cautious technical signal.
- Over the past three years, ALNY has underperformed the S&P 500 by −38.44%, with a relative strength index reading of 77.6.
- Win rate over the trailing 39 months stands at 43.6% — 17 positive months versus 22 negative months.
Alnylam Pharmaceuticals ended September 2026 at $239.56, posting a monthly return of −0.47%. The S&P 500 returned −0.70% over the same window, leaving relative performance at +0.23%.
The current quarter stands at −20.42% (Q3 2026 (QTD)), while medium-term trend remains soft: price is −24.33% versus the 200-day moving average ($316.57).
Year-to-date, ALNY is −39.76% against SPY +11.70%, a gap of −51.45%. The stock is currently −51.66% below its 52-week high, with maximum 3-year drawdown at −58.17%.
| Period | ALNY | S&P 500 (SPY) | Excess return |
|---|---|---|---|
| 1 Day | −2.42% | −0.12% | −2.30% |
| 1 Week | −3.67% | −0.34% | −3.33% |
| 1 Month | −0.47% | −0.70% | +0.23% |
| 3 Months | −16.76% | +2.80% | −19.56% |
| 6 Months | −24.48% | +13.85% | −38.33% |
| YTD | −39.76% | +11.70% | −51.45% |
| 12 Months | −47.02% | +15.01% | −62.03% |
| 3 Years | +33.26% | +71.69% | −38.44% |
| Rank | Month | Return |
|---|---|---|
| #1 | Jun 2024 | +63.71% |
| #2 | Jul 2025 | +20.29% |
| #3 | Aug 2026 | +17.11% |
| #4 | May 2025 | +15.70% |
| #5 | Jan 2025 | +15.30% |
| Rank | Month | Return |
|---|---|---|
| #1 | Jul 2026 | −31.73% |
| #2 | Jan 2026 | −14.99% |
| #3 | Oct 2023 | −14.29% |
| #4 | Feb 2024 | −12.62% |
| #5 | Dec 2025 | −11.87% |
| Quarter | Return |
|---|---|
| Q2 2025 | +20.77% |
| Q3 2025 | +39.84% |
| Q4 2025 | −12.80% |
| Q1 2026 | −16.79% |
| Q2 2026 | −9.02% |
| Q3 2026 (QTD) | −20.42% |
| Year | Return |
|---|---|
| 2023 | −19.46% |
| 2024 | +22.94% |
| 2025 | +68.99% |
| 2026 | −39.76% |
| Metric | Value |
|---|---|
| 52-Week High | $495.55 (2025-10-20) |
| 52-Week Low | $197.81 (2026-07-30) |
| Current Price | $239.56 |
| 200-Day Moving Average | $316.57 |
| Price vs 200DMA | −24.33% |
| 3-Year Maximum Drawdown | −58.17% (2026-07-30) |
| Current Drawdown from 52W High | −51.66% |
| RS metric | Value |
|---|---|
| RS Index (3-year, rebased to 100) | 77.6 |
| 3-Year Excess Return vs S&P 500 | −38.44% |
| RS Peak | 183 (Sep 2025) |
| RS Trough | 67.9 (Jul 2026) |
| Status | Underperforming Benchmark |
Frequently asked questions
What was ALNY's return for this report period?
ALNY returned −0.47% in the latest monthly window ending 2026-09-18.
Has ALNY outperformed SPY year to date?
YTD ALNY: −39.76% vs SPY: +11.70%.
What is ALNY's 12-month return?
−47.02% over the trailing 12 months.
Is ALNY above or below its 200-day moving average?
Price is −24.33% versus 200DMA ($316.57).
What is the maximum drawdown in the 3-year window?
−58.17% on 2026-07-30.